Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance.

Lucien TorlotAnna JarzabJohanna AlbertÁgnes Pók-UdvariArndt StahlerJulian Walter HolchMarco GerlingerVolker HeinemannFrederick KlauschenThomas KirchnerJörg KumbrinkBernhard KüsterAndreas Jung

Published in: Journal of cancer research and clinical oncology (2022)

These results highlight EPHA2 and its role in mCRC with KRAS-gene mutated acquired CET resistance and support its use as a potential actionable target for the development of future precision medicine therapies.

Keyphrases

wild type
mass spectrometry
human health
current status
copy number
squamous cell carcinoma
gene expression
locally advanced
radiation therapy
transcription factor